Endotoxin Testing Market Report 2026

The endotoxin testing market size has grown strongly in recent years. It will grow from $2.31 billion in 2025 to $2.44 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to drug safety regulations, growth in pharmaceutical manufacturing, medical device quality standards, patient safety concerns, laboratory testing expansion.

The endotoxin testing market size is expected to see strong growth in the next few years. It will grow to $3.12 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to biologic drug growth, stricter regulatory audits, automation in quality testing, medical device innovation, contamination risk management. Major trends in the forecast period include rising focus on pharmaceutical safety, increased regulatory compliance requirements, growth in medical device quality testing, expansion of in vitro diagnostic testing, demand for accurate endotoxin detection.

The rising incidence of healthcare-associated infections (HAIs) is expected to drive the growth of the endotoxin testing market in the coming years. HAIs are infections acquired during medical care that were not present at the time of hospital admission. The increasing occurrence of HAIs is driven by inadequate infection prevention and control practices, exposure to contaminated medical devices, and the growing prevalence of drug-resistant pathogens. Endotoxin testing enhances patient safety by detecting bacterial endotoxins in medical equipment, injectable drugs, and implantable devices, thereby reducing the risk of sepsis, inflammation, and device-related complications. For example, in November 2024, the World Health Organization (WHO), a Switzerland-based public health agency, reported in its Global Report on Infection Prevention and Control 2024 that although 71% of countries have active IPC programs, only 6% met all WHO minimum IPC requirements in 2023-2024, leaving millions of patients at increased risk of HAIs. Consequently, the growing prevalence of healthcare-associated infections is contributing to the expansion of the endotoxin testing market.

Key companies in the endotoxin testing market are focusing on developing advanced solutions, such as integrated absorbance microplate readers, to improve testing accuracy, streamline laboratory workflows, and ensure compliance with data integrity standards. Advanced absorbance readers are instruments designed to integrate with specialized assay software, support validated workflows, and provide consistent results in accordance with industry requirements. For instance, in August 2023, Lonza Group AG, a Switzerland-based pharmaceutical, biotechnology, and nutrition manufacturer, launched the Nebula Absorbance Reader, a next-generation microplate reader developed to simplify endotoxin and pyrogen testing. Fully integrated with Lonza’s latest WinKQCL software, the system supports data integrity compliance, reduces validation efforts, and minimizes training requirements by allowing existing WinKQCL users to operate the reader without additional software learning. Designed as a technologically advanced replacement for the discontinued ELx808 absorbance reader, the Nebula platform delivers comparable performance and is optimized for Lonza’s absorbance-based endotoxin assays, including the PYROGENT 5000 Turbidimetric and Kinetic-QCL Chromogenic Endotoxin Assays.

In September 2024, Eurofins Scientific SE, a Luxembourg-based bio-analytical testing organization, acquired Infinity Laboratories Inc. for an undisclosed amount. Through this acquisition, Eurofins aims to enhance its microbiology and endotoxin testing capabilities by integrating Infinity Laboratories’ network of eight U.S.-based microbiology testing facilities and its team of approximately 100 professionals. Infinity Laboratories Inc. is a US-based company that provides comprehensive endotoxin testing services.

Major companies operating in the endotoxin testing market are Thermo Fisher Scientific Inc., Merck KGaA, bioMérieux SA., Eurofins Scientific SE, Lonza Group Ltd., WuXi AppTec Co. Ltd., Bio-Rad Laboratories Inc., Maravai LifeSciences Holdings Inc., Cambrex Corporation, GenScript Biotech Corporation, Charles River Laboratories International Inc., Nelson Laboratories LLC, Lifecore Biomedical Inc., Stellar Biotechnologies Inc., Biovision Inc., Associates of Cape Cod Inc., FUJIFILM Wako Pure Chemical Corporation, InvivoGen Inc., Tebu-bio Nv., MatTek Corporation, Microcoat Biotechnologie GmbH, Accelagen Inc., BioAssay Systems LLC, BioThema AB, Hycult Biotech Inc., Pacific Biolabs Inc., Xiamen Bioendo Technology Co. Ltd., Zhanjiang A&C Biological Ltd., Accugen Laboratories Inc.

North America was the largest region in the endotoxin testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endotoxin testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the endotoxin testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the endotoxin testing market by increasing costs of imported testing kits, reagents, and laboratory instruments. Pharmaceutical manufacturers and laboratories in developed regions are most affected due to reliance on imported assay materials. These tariffs raise compliance costs by increasing quality control and regulatory testing expenses. However, they support domestic production of testing reagents, improving supply reliability for pharmaceutical manufacturing.

The endotoxin testing market research report is one of a series of new reports that provides endotoxin testing market statistics, including endotoxin testing industry global market size, regional shares, competitors with a endotoxin testing market share, detailed endotoxin testing market segments, market trends and opportunities, and any further data you may need to thrive in the endotoxin testing industry. This endotoxin testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Endotoxin testing, also known as the bacterial endotoxins test (BET), is an in vitro assay used to measure bacterial endotoxin levels in substances, particularly in pharmaceuticals and medical devices, to ensure safety and adherence to quality standards. This testing is critical for preventing potential harmful effects on patients and users.

The main types of endotoxin testing include LAL (limulus amebocyte lysate) tests, chromogenic tests, turbidimetric tests, gel clot tests, MAT tests, rabbit pyrogen tests, and recombinant factor C (rFC) assays. The LAL test is a highly sensitive assay that detects bacterial endotoxins in medical and pharmaceutical products by utilizing the clotting reaction of horseshoe crab blood components. Endotoxin testing is applied in various areas, including medical devices, pharmaceuticals, packaging, and raw materials, and is utilized by multiple end users such as hospitals, laboratories, and research institutes.

The endotoxin testing market consists of revenues earned by entities by providing contract testing services, ecologically sustainable testing and rapid testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The endotoxin testing market also includes sales of injectable pharmaceutical products, endotoxin detection systems, limulus amebocyte lysate test reagents and polymerase chain reaction mycoplasma detection kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.